Navigation Links
First results from major European patient survey show devastating impact of living with breakthrough cancer pain
Date:9/11/2009

Lisbon, Portugal 11 September, 2009 The first results of the first European survey of cancer patients experience of breakthrough pain were presented today at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC).

Previous surveys have looked at the overall management of pain in cancer patients but this is the first international study to look in detail at Breakthrough Cancer Pain (BTCP) from a patient perspective. These results for the first 200 patients from the UK, Sweden and Denmark offer valuable insight into cancer patients experiences with breakthrough pain management and the impact of the condition on their daily lives.

  • The median number of BTCP episodes per patient per day was 3
  • Each episode had a median duration of 60 minutes
  • 96% of the pain episodes were described as moderate to severe
  • For 90% of patients their BTCP interfered with their daily living including their ability to sleep, walk and get on with other people

The study documents that breakthrough pain has a significant impact on cancer patients daily lives, explained Dr. Andrew Davies, Department of Palliative Medicine, Royal Marsden Hospital, UK and the principal investigator of this survey. Breakthrough pain is very different to background pain. Background pain is a continuous, chronic pain requiring around-the-clock medication. Breakthrough pain is a fast onset, short duration, intense pain that breaks through the chronic pain even when this is being controlled with medication. It is incapacitating and very distressing to the patient.

For this kind of pain episode the ideal treatment would be fast acting with a short duration of action to most closely match the nature of BTCP episodes. Moreover, it must be easy to use to improve patient compliance. However, the results of the survey show that:

  • At least 95% of patients were using orally administered drugs
  • The time to first noticing a reduction in pain had a median time of 20 minutes
  • In this survey the median time to peak effect of the current BTCP rescue medications was 30 minutes

Oral opioids are still commonly used to manage BTCP despite the fact that the way these drugs work does not match the characteristics of a BTCP episode. Opioids given by other routes, for example intranasal, have significant advantages over oral opioids and the interim results from this survey suggest that these routes would be suitable for and welcomed by the majority of cancer patients with breakthrough pain said Dr. Andrew Davies.


'/>"/>

Contact: Mette Thorn Srensen
mts@cohnwolfe.dk
454-138-4300
Cohn & Wolfe, Copenhagen
Source:Eurekalert

Related medicine news :

1. Tampa Personal Injury Lawyer Timothy Anderson, Jr. Joins Father's Law Firm, Takes Five Cases To Jury Trial In First Eighteen Months
2. NorthShore University HealthSystem First in Illinois to Perform Remarkable Robotic Arm Guided Partial Knee Replacement Surgery
3. LifeNet Health and Childrens Mercy Hospital Announce First Implant With MatrACELL(TM) Technology
4. The CRIMSON Initiative - the First Physician Performance Data Management Platform Developed By Physicians For Physicians - is Now Working With Over 200 Hospitals and Over 25,000 Doctors
5. First Cape Cod Macular Degeneration Symposium To Be Held on September 17
6. Regado Biosciences Announces First Patient Enrolled in RADAR (Phase 2b) Study of REG1 Anticoagulation System
7. First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain
8. Allscripts to Announce Fiscal First Quarter Results on September 29, 2009; Company Appoints Vice President of Investor Relations
9. Meda Introduces EDLUAR(TM), the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication, Zolpidem Tartrate
10. First-Ever NJ Psoriasis Walk Coming to Paramus on Sept. 12
11. RBC Life Sciences Unveils the ClearPay System - the Industrys First Balancing Compensation Plan That Pays Quickly and Abundantly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
(Date:9/22/2017)... ROCKVILLE, Md. , Sept. 22, 2017  As ... by Republican Senators Bill Cassidy (R-LA) and ... Kalorama Information notes that the medical device industry is ... the medical device tax, the 2.3% excise tax on ... Act.  But they also want covered patients, increased visits ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
Breaking Medicine Technology: